Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis
Go back to Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis| Regeneron (NASDAQ: REGN) | Delayed: 784.85 -4.6 (0.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $789.45 | 52 Week High | $592.36 | |||
| Open | $787.34 | 52 Week Low | $325.35 | |||
| Day High | $794.73 | P/E | 206.00 | |||
| Day Low | $779.65 | EPS | $3.81 | |||
| Volume | 2,473,425 | |||||
